A Pragmatic Approach to Introducing Translational Geroscience Into the Clinic: A Paradigm Based on the Incremental Progression of Aging-Related Clinical Research

Прагматический подход к внедрению трансляционной геронауки в клиническую практику: парадигма, основанная на поэтапном развитии клинических исследований, связанных со старением
Daniel E. Forman, Robert J. Pignolo
2024-08-10

Longevity Clinicsaging-related clinical researchcanakinumabgerotherapeuticstranslational geroscience
Geroscience posits that molecular drivers underlie the aging process. Gerotherapeutics entail strategies to counter molecular drivers of aging to reduce the chronic diseases and geriatric syndromes they trigger. Although the concept of gerotherapeutics for prevention has generated much excitement, the implications of prescribing potentially harmful medications to older adults who are "healthy" have been associated with many delays. Concerns regarding safety and valid endpoints have contributed to holdups. In contrast, it has been relatively easier to implement trials of medications with gerotherapeutic properties as novel approaches to remedy disease. In these applications, the risks of the medications are easier to justify when therapeutic benefits are perceived as outweighing the harms of the disease. Likewise, metrics of effective disease treatments are often seen as more reliable and quantifiable than metrics of health prolongation. Overall, clarifying geroscience mechanisms in disease therapeutic applications provides key opportunities to advance translational geroscience, especially as preventive geroscience trials are often encumbered. In this review, gerotherapeutic benefits of canakinumab, cholchicine, and zoledronic acid as parts of disease management are considered. Longevity Clinics and other opportunities to advance translational geroscience as parts of contemporary care are also discussed.
1
Canakinumab, colchicine, zoledronic acid, and emerging Longevity Clinics are identified as opportunities for integrating gerotherapeutic strategies into contemporary care.
2
Disease-treatment outcomes are generally considered more reliable and quantifiable than measures of prolonged healthspan.
3
Gerotherapeutics are more readily tested in disease-treatment settings, where medication risks can be justified against expected therapeutic benefits.
4
Preventive gerotherapeutic trials face delays because prescribing potentially harmful medications to healthy older adults raises safety and endpoint-validity concerns.
5
Translational geroscience can advance incrementally by clarifying geroscience mechanisms through therapeutic applications in diseases.

Translational geroscience and gerotherapeutic interventions integrated into clinical disease management and contemporary care

The clinical translation, benefits, safety, and evaluation of gerotherapeutics for treating disease and advancing aging-related care

Publication Details
Publication Date
2024-08-10
Journal
Publisher
ISSN
Cited by
8
Access Type
Author Information
Authors
Daniel E. Forman
Robert J. Pignolo
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%